BCL2 and acute myeloid leukemia: Of note, BCL-2 inhibition via therapeutics like the BCL-2 inhibitor Venetoclax sensitizes cancer cells to apoptosis and has become indispensable for oncological treatment in Chronic Lymphocytic Leukemia (CLL) or Acute Myeloid Leukemia (AML) [14,15,16,17].